Isolated bispecific antibody, and its production method, isolated nucleic acid, expression vector, host cell for producing the antibody or antigen-binding fragment and its production method, and pharmaceutical composition.
Bispecific antibodies with tailored antigen-binding fragments and engineered Fc regions address the need for new CD3-tumor antigen binders, enhancing therapeutic efficacy by targeting tumor cells with high specificity and affinity.
BR112025019165A2Pending Publication Date: 2026-07-07JOINT CO BIOCAD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- BR112025019165
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-10
- Filing Date
- 2024-03-07
- Publication Date
- 2026-07-07
Smart Images
Figure 00000246_0000 
Figure 00000246_0001 
Figure 00000246_0002
Abstract
The present invention relates to the field of biotechnology and medicine, in particular to a bispecific antibody that specifically binds to CD3 and a tumor antigen. The invention further relates to a nucleic acid encoding the subject bispecific antibody, an expression vector, a host cell for producing the subject bispecific antibody and a method for producing said cell, pharmaceutical compositions comprising the bispecific antibody according to the invention, pharmaceutical compositions comprising the bispecific antibody according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by a tumor antigen, use of the bispecific antibody or pharmaceutical compositions thereof for treating diseases or disorders mediated by a tumor antigen, and the use of the bispecific antibody according to the invention and other therapeutically active compounds for treating diseases or disorders mediated by a tumor antigen.
Need to check novelty before this filing date? Find Prior Art